National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Natpar is indicated as adjunctive treatment of adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone.

NCPE Assessment Process Complete
Rapid review commissioned 05/03/2018
Rapid review completed 21/05/2018
Rapid Review outcome A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of Natpar compared with the current standard of care.

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.